Cellectar Biosciences (CLRB) News
NASDAQ: CLRBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CLRB news summary
We found 4 recent headlines mentioning Cellectar Biosciences (CLRB): 0 in the past week and 3 in the past 30 days, most often from GlobeNewswire, Nasdaq. CLRB is making an outsized move today, down 11.50% at $0.797, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Cellectar Biosciences Q3 Loss Widens; Eyes FDA Filing For Iopofosine I-131 In H1 2027", was published by Nasdaq on Nov 11, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Cellectar Biosciences headlines
- Cellectar Biosciences Q3 Loss Widens; Eyes FDA Filing For Iopofosine I-131 In H1 2027(RTTNews) - Cellectar Biosciences, Inc. (CLRB), a late-stage clinical biopharmaceutical company, reported third-quarter financial results for the quarter ended September 30, 2026, reflecting a wider…NasdaqCLRB, ET
- Cellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatesPresented updated data at the International Workshop for Waldenström Macroglobulinemia (IWWM) supporting the planned accelerated approval strategy for iopofosine I 131 in Waldenström…GlobeNewswire
- Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131Durable Complete Response Achieved with Single Administration of Iopofosine I 131GlobeNewswire
- Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström MacroglobulinemiaSubgroup analysis of patients who received Bruton Tyrosine Kinase inhibitor (BTKi) treatment immediately prior to iopofosine I 131 achieved 87.5% ORR, 79.2% MRR and 100% CBR with median DOR of 16…GlobeNewswire